Northwest Biotherapeutics, Inc. (NWBO)
- Previous Close
0.2712 - Open
0.2670 - Bid --
- Ask --
- Day's Range
0.2620 - 0.2750 - 52 Week Range
0.1700 - 0.5000 - Volume
1,559,864 - Avg. Volume
3,948,820 - Market Cap (intraday)
391.052M - Beta (5Y Monthly) -1.09
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0600 - Earnings Date Aug 7, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types of cancers. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
www.nwbio.comRecent News: NWBO
View More
Performance Overview: NWBO
Trailing total returns as of 6/3/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NWBO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NWBO
View MoreValuation Measures
Market Cap
389.90M
Enterprise Value
456.13M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
236.60
Price/Book (mrq)
--
Enterprise Value/Revenue
309.66
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-151.76%
Return on Equity (ttm)
--
Revenue (ttm)
1.47M
Net Income Avi to Common (ttm)
-85.92M
Diluted EPS (ttm)
-0.0600
Balance Sheet and Cash Flow
Total Cash (mrq)
2.78M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-30.13M